Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Protocol: Alliance – A151804 SCHEMA A151804 Please Note:  Below is a partial list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss the full list of eligibility requirements.  Thank  you! Eligibility: Received a regimen containing one or more immuno-oncology therapeutics. Has not previously been […]

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer

Protocol: SWOG – S2010 SCHEMA S2010 Please Note:  Below is only a partial list of eligibility requirements, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss full eligibility requirements.  Thank you! Eligibility: Participants must be female and have Stage I, II, or III hormone receptor positive […]

Blinded Reference Set for Multicancer Early Detection Blood Tests

Protocol: Alliance – A212102 SCHEMA A022102 Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Criteria for Participants with a Cancer Diagnosis Histologically confirmed diagnosis of invasive cancer. Stage I-IV. One of the following tumor types: Head […]

Internet Delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

Protocol: WF-1901 SCHEMA WF-1901 Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: 1. Must have a documented diagnosis of invasive cancer that has been treated with either single modality therapy or any combination of surgery, radiation, […]

A Phase II Randomized Double Blinded Study of Green Tea Catechins Versus Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Protocol: ECOG – EA8184 SCHEMA EA8184 Please Note: Below is partial eligibility, for full eligibility requirements, please contact Genesys Hurley Cancer Institute Research Department at (810) 762-8181, (810) 762-8079, and/or (810) 762-8038. Thank you! Eligibility: (Step 0: Screening): 1. Patient must be ≥ 21 years of age. 2. Patient must speak English or Spanish. 3. […]

A Randomized Trial Addressing Cancer Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention

Protocol: SWOG – S1912CD SCHEMA S1912CD Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Patients must have a diagnosis of a metastatic solid tumor or a hematologic malignancy and must receive anti-cancer treatment per the timing described […]

A Randomized, Double Blind, Placebo Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

Protocol: Alliance – A222001 SCHEMA A222001 Please Note: Below is partial eligibility, please contact GHCI Research Department for full eligibility requirements at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Men who are currently receiving androgen deprivation therapy for the treatment of prostate cancer. Patients must be on a stable dose of all […]

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer Associated Anorexia

Protocol: Alliance – A222004 SCHEMA A222004 Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Diagnosis of advanced cancer. Patient report 2 month weight loss of at least 5 pounds (2.3 kilograms) and/or physician estimated caloric intake of less than 20 […]

Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue

PROTOCOL: URCC-18007 SCHEMA URCC-18007 Please Note: Below partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! ELIGIBILITY: Be female at least 18 years of age. Been diagnosed with Stage I-III breast cancer. Be currently breast cancer-free. Report moderate to severe fatigue in the past week. Attribute […]